Department of Basic Medical Sciences,University of Bari Medical School, Policlinico, Bari, Italy.
Curr Med Chem. 2012;19(7):955-60. doi: 10.2174/092986712799320655.
The immune system regulates angiogenesis in cancer by means of pro- and anti-angiogenesis activities. In fact, both innate (macrophages, granulocytes, mast cells, dendritic cells, natural killer cells, and platelets) and adaptive (T and B lymphocytes) immune cells synthesize several pro- and anti-angiogenic mediators. Moreover, in pre-clinical models, a synergy has been observed between antiangiogenic molecules and immunotherapy. In this review article, we will focus on some angiogenenic and anti-angiogenic molecules properties of immune cells that may be utilized for a potential parmacological use as anti-angiogenic agents in cancer.
免疫系统通过促进和抑制血管生成活动来调节癌症中的血管生成。事实上，先天（巨噬细胞、粒细胞、肥大细胞、树突状细胞、自然杀伤细胞和血小板）和适应性（T 和 B 淋巴细胞）免疫细胞都合成几种促血管生成和抗血管生成的介质。此外，在临床前模型中，抗血管生成分子与免疫疗法之间观察到协同作用。在这篇综述文章中，我们将重点介绍一些免疫细胞的血管生成和抗血管生成分子的特性，这些特性可能被用作癌症中潜在的抗血管生成药物。
